Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
出版年份 2021 全文链接
标题
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume 39, Issue 36, Pages 4073-4126
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2021-11-02
DOI
10.1200/jco.21.01440
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cutaneous immune‐related adverse events in patients with melanoma treated with checkpoint inhibitors
- (2021) A. Gault et al. BRITISH JOURNAL OF DERMATOLOGY
- Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy
- (2021) Monika F. Keiser et al. Clinical Lung Cancer
- Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society
- (2021) Takeshi Johkoh et al. RADIOLOGY
- Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis
- (2021) Fangwen Zou et al. Journal for ImmunoTherapy of Cancer
- Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival
- (2021) Tamara A Sussman et al. Journal for ImmunoTherapy of Cancer
- Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
- (2021) Aanika Balaji et al. Journal for ImmunoTherapy of Cancer
- Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors
- (2021) Anusha S. Thomas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
- (2021) Jason Beattie et al. Journal for ImmunoTherapy of Cancer
- Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum
- (2020) Divyanshu Dubey et al. ANNALS OF NEUROLOGY
- A review of cancer immunotherapy toxicity
- (2020) Lucy Boyce Kennedy et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Immune-related adverse events and efficacy outcomes in patients treated with immunotherapy: A systematic review and meta-analysis.
- (2020) Eric Druyts et al. JOURNAL OF CLINICAL ONCOLOGY
- It Is Time to Talk About Fertility and Immunotherapy
- (2020) Narjust Duma et al. ONCOLOGIST
- Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy
- (2020) Xiaowei Liu et al. Thoracic Cancer
- Cancer patients’ experiences with immune checkpoint modulators: A qualitative study
- (2020) Kari Ala‐Leppilampi et al. Cancer Medicine
- Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma
- (2020) Sarah Abou Alaiwi et al. Journal for ImmunoTherapy of Cancer
- EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
- (2020) Marie Kostine et al. ANNALS OF THE RHEUMATIC DISEASES
- Autoantibodies as predictors for survival and immune-related adverse events in checkpoint inhibition therapy of metastasized melanoma.
- (2020) Jessica Cecile Hassel et al. JOURNAL OF CLINICAL ONCOLOGY
- Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors.
- (2020) Qian Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Cutaneous adverse reactions to anti-PD-1 treatment – a systematic review
- (2020) Anne Birgitte Simonsen et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- CME Part II: Immune checkpoint inhibitor-related dermatologic adverse events
- (2020) Amaris N. Geisler et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
- (2020) Giancarlo Agnelli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Demographic factors associated with toxicity in patients treated with anti-programmed cell death-1 therapy
- (2020) Kaustav P Shah et al. Cancer Immunology Research
- Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
- (2020) Charles Dolladille et al. JAMA Oncology
- Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors
- (2020) Maha Mamoor et al. Journal for ImmunoTherapy of Cancer
- COVID-19 and immune checkpoint inhibitors: initial considerations
- (2020) Ryan J Sullivan et al. Journal for ImmunoTherapy of Cancer
- Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
- (2020) J. Haanen et al. ANNALS OF ONCOLOGY
- Cutaneous immune-related adverse events to checkpoint inhibitors
- (2020) Neeta Malviya et al. CLINICS IN DERMATOLOGY
- Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management
- (2020) Anastasiya Muntyanu et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- ISTH Guidelines for the Diagnosis of Thrombotic Thrombocytopenic Purpura
- (2020) X. Long Zheng et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Ralf Gutzmer et al. LANCET
- Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic
- (2020) Hsu-Liang Chang et al. LUNG CANCER
- Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy
- (2020) Khashayar Esfahani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
- (2020) Emanuel Raschi et al. Targeted Oncology
- Chronic immune checkpoint inhibitor pneumonitis
- (2020) Jarushka Naidoo et al. Journal for ImmunoTherapy of Cancer
- Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients
- (2020) Stefania Cuzzubbo et al. Journal for ImmunoTherapy of Cancer
- Incidence, risk factors and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy
- (2020) Florian Moik et al. BLOOD
- Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
- (2020) Ying Jing et al. Nature Communications
- Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis
- (2020) Syed Hussaini et al. CANCER TREATMENT REVIEWS
- Abstract 15395: Immune Checkpoint Inhibitors for Cancer Are Associated With Increased Venous Thromboembolism Events
- (2020) Jingyi Gong et al. CIRCULATION
- Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors
- (2020) Jeffrey Aldrich et al. Arthritis & Rheumatology
- Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer
- (2020) Bairavi Shankar et al. JAMA Oncology
- Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis
- (2020) Jennifer Cautela et al. Journal for ImmunoTherapy of Cancer
- Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
- (2020) Marion Allouchery et al. Journal for ImmunoTherapy of Cancer
- KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
- (2020) Pier Francesco Ferrucci et al. Journal for ImmunoTherapy of Cancer
- The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients
- (2020) Si-Qi Tang et al. Cancer Research and Treatment
- Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series
- (2019) Abdul Rafeh Naqash et al. Journal for ImmunoTherapy of Cancer
- Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab
- (2019) Hao Chi Zhang et al. Journal for ImmunoTherapy of Cancer
- Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
- (2019) Hamzah Abu-Sbeih et al. Journal for ImmunoTherapy of Cancer
- Hematologic Complications of Immune Checkpoint Inhibitors
- (2019) Elizabeth J. Davis et al. ONCOLOGIST
- Combined immune therapy grade IV dermatitis in metastatic melanoma
- (2019) Manreet Randhawa et al. Asia-Pacific Journal of Clinical Oncology
- Severe immune related adverse events are common with sequential PD-(L)1 blockade and osimertinib
- (2019) A J Schoenfeld et al. ANNALS OF ONCOLOGY
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- (2019) J Mazières et al. ANNALS OF ONCOLOGY
- Post-shingles granulomatous dermatosis related to anti-programmed cell death 1
- (2019) Tarek Assi et al. Immunotherapy
- Dermal elastolysis in the setting of combination immunotherapy
- (2019) Kirsten E Dickinson et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors
- (2019) Min Xu et al. NEUROLOGIST
- Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy
- (2019) Blake M. Warner et al. ONCOLOGIST
- Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors
- (2019) Tenglong Tang et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors
- (2019) Aine O’Reilly et al. SUPPORTIVE CARE IN CANCER
- Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare
- (2019) Sang T. Kim et al. Journal for ImmunoTherapy of Cancer
- Cutaneous Adverse Reactions of Anticancer Agents
- (2019) Subuhi Kaul et al. DERMATOLOGIC CLINICS
- Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma
- (2019) Erika F. Rodriguez et al. HUMAN PATHOLOGY
- Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
- (2019) Hamzah Abu-Sbeih et al. JOURNAL OF CLINICAL ONCOLOGY
- Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy
- (2019) Khashayar Esfahani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis
- (2019) Joe-Elie Salem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
- (2019) Nigel S. Key et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline
- (2019) Charles L. Shapiro et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma
- (2019) Meredith M. Regan et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune checkpoint inhibitors‐induced neuromuscular toxicity: from pathogenesis to treatment
- (2019) Dimitri Psimaras et al. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
- Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System
- (2019) Emanuel Raschi et al. ONCOLOGIST
- Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer
- (2019) Giulia Galli et al. TUMORI
- Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study
- (2019) Alice Tison et al. Arthritis & Rheumatology
- Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer
- (2019) Deniz C Guven et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Radiation-Induced Lung Injury (RILI)
- (2019) Lorena Giuranno et al. Frontiers in Oncology
- The Future of Immunotherapy in the Treatment of Cancer
- (2019) Lisa A. Kottschade Seminars in Oncology Nursing
- Variations of Diagnosis and Management of Immune Checkpoint Inhibitor Pancreatic Injury (ICIPI) and Immune Checkpoint Inhibitor Pancreatitis: A Single Institution Experience
- (2019) Ravi Shah et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study
- (2019) Samy Babai et al. DRUG SAFETY
- Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
- (2019) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook
- (2019) Nora Möhn et al. Journal of Clinical Medicine
- Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors
- (2019) Yosuke Ando et al. INVESTIGATIONAL NEW DRUGS
- Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis
- (2019) Puyuan Xing et al. Journal for ImmunoTherapy of Cancer
- Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
- (2019) Federico Nichetti et al. Cancers
- Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease
- (2018) Noha Abdel-Wahab et al. ANNALS OF INTERNAL MEDICINE
- Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials
- (2018) Karen Kelly et al. CANCER
- High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma
- (2018) Alexander T. Faje et al. CANCER
- Cutaneous toxicities of new treatments for melanoma
- (2018) A. Boada et al. Clinical & Translational Oncology
- Vasculitis associated with immune checkpoint inhibitors—a systematic review
- (2018) Anisha Daxini et al. CLINICAL RHEUMATOLOGY
- Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis
- (2018) Yinghong Wang et al. INFLAMMATORY BOWEL DISEASES
- A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors
- (2018) Adriana T. Lopez et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction
- (2018) Kei Kunimasa et al. INVESTIGATIONAL NEW DRUGS
- Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update
- (2018) Kutluk Oktay et al. JOURNAL OF CLINICAL ONCOLOGY
- Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline
- (2018) Jeanne Carter et al. JOURNAL OF CLINICAL ONCOLOGY
- Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern
- (2018) Celestine Trinidad et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Granulomatous dermatitis associated with ipilimumab therapy (ipilimumab associated granulomatous dermatitis)
- (2018) Shelby L. Kubicki et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study
- (2018) Charles Kyung Min Lee et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
- (2018) Jacob Siegel et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
- (2018) Sara Valpione et al. Journal of Translational Medicine
- A Case of Nivolumab‐Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein‐1/Programmed Death Ligand‐1 Inhibitors and Recommendations for Diagnosis and Management
- (2018) Adriana T. Lopez et al. ONCOLOGIST
- Myositis as an adverse event of immune checkpoint blockade for cancer therapy
- (2018) Mohsin Shah et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study
- (2018) Taku Fujimura et al. Oncotarget
- Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases
- (2018) Marie Donaldson et al. JAMA Dermatology
- Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy
- (2018) Leo L. Wang et al. JAMA Dermatology
- Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies
- (2018) Chun-Bing Chen et al. Cancer Management and Research
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy
- (2018) William L. Hwang et al. JAMA Oncology
- Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis
- (2018) Fausto Petrelli et al. EUROPEAN JOURNAL OF CANCER
- Drug-induced oral lichenoid reaction during nivolumab therapy
- (2018) Y. Enomoto et al. INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
- Off treatment survival (OTS) in patients (pts) with advanced melanoma after anti-PD1 therapy.
- (2018) Shelly Ann Christiansen et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy
- (2018) Andrew Hwang et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
- (2018) Hamzah Abu-Sbeih et al. Journal for ImmunoTherapy of Cancer
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- (2018) Mario Lacouture et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- (2018) C. Grávalos et al. Clinical & Translational Oncology
- Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy
- (2018) Su Y. Lim et al. CLINICAL CANCER RESEARCH
- Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
- (2018) Yinghong Wang et al. NATURE MEDICINE
- Diagnosis and Management of Immune Checkpoint Inhibitor‐Associated Neurologic Toxicity: Illustrative Case and Review of the Literature
- (2018) Kerry L. Reynolds et al. ONCOLOGIST
- Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
- (2017) S. Cuzzubbo et al. EUROPEAN JOURNAL OF CANCER
- Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment
- (2017) Laura C Cappelli et al. Immunotherapy
- Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline
- (2017) Timothy Gilligan et al. JOURNAL OF CLINICAL ONCOLOGY
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
- (2017) Jarushka Naidoo et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
- (2017) Mario Sznol et al. JOURNAL OF CLINICAL ONCOLOGY
- Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2017) Betty R. Ferrell et al. JOURNAL OF CLINICAL ONCOLOGY
- Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients
- (2017) Michael T. Tetzlaff et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity
- (2017) Ryota Tanaka et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids
- (2017) Mirjana Ziemer et al. JOURNAL OF HEPATOLOGY
- Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors
- (2017) Sophie Feng et al. Journal of Thoracic Oncology
- New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma
- (2017) Juliane Behling et al. MELANOMA RESEARCH
- Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab
- (2017) Richard Barnett et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis
- (2017) Animesh Jain et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
- (2017) Laura C. Cappelli et al. ARTHRITIS CARE & RESEARCH
- Hair Repigmentation During Immunotherapy Treatment With an Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Agent for Lung Cancer
- (2017) Noelia Rivera et al. JAMA Dermatology
- Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies
- (2017) Justin C. Kao et al. JAMA Neurology
- Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer
- (2017) Maria E. Suarez-Almazor et al. Arthritis & Rheumatology
- Cardiovascular Toxicities Associated with Cancer Immunotherapies
- (2017) Daniel Y. Wang et al. Current Cardiology Reports
- Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
- (2017) Vivek Kumar et al. Frontiers in Pharmacology
- Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
- (2017) Sarah Chuzi et al. Cancer Management and Research
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide
- (2017) D. Berman et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma
- (2017) J. S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma.
- (2017) R. A. Ibrahim et al. JOURNAL OF CLINICAL ONCOLOGY
- Left Ventricular Dysfunction After Treatment With Ipilimumab for Metastatic Melanoma
- (2016) Mary E. Roth et al. AMERICAN JOURNAL OF THERAPEUTICS
- Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy
- (2016) C. L. Boils et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection
- (2016) T. Alhamad et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature
- (2016) L. Spain et al. ANNALS OF ONCOLOGY
- Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
- (2016) L. Spain et al. ANNALS OF ONCOLOGY
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- (2016) A. M. Menzies et al. ANNALS OF ONCOLOGY
- Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
- (2016) Laura C Cappelli et al. ANNALS OF THE RHEUMATIC DISEASES
- Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases
- (2016) Leonard Calabrese et al. ANNALS OF THE RHEUMATIC DISEASES
- Pulmonary sarcoid-like granulomatosis induced by nivolumab
- (2016) H. Montaudié et al. BRITISH JOURNAL OF DERMATOLOGY
- Faecal calprotectin in patients with suspected colorectal cancer: a diagnostic accuracy study
- (2016) James Turvill et al. BRITISH JOURNAL OF GENERAL PRACTICE
- Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma
- (2016) François-Xavier Danlos et al. CHEST
- Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis
- (2016) Eduard Cornelis Verschuren et al. Clinical Gastroenterology and Hepatology
- Programmed cell death-1 pathway inhibitors in genitourinary malignancies
- (2016) Abhishek Tripathi et al. CURRENT OPINION IN UROLOGY
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
- (2016) Maria Fleseriu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline
- (2016) Stefan R. Bornstein et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
- (2016) L. Marthey et al. Journal of Crohns & Colitis
- Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
- (2016) Frank B. Cortazar et al. KIDNEY INTERNATIONAL
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus
- (2016) Kyoko Inadomi et al. MEDICINE
- Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia
- (2016) Ranjit Nair et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Regression and Allograft Rejection after Administration of Anti–PD-1
- (2016) Evan J. Lipson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monitoring and Management of Immune‐Related Adverse Events Associated With Programmed Cell Death Protein‐1 Axis Inhibitors in Lung Cancer
- (2016) Grainne M. O'Kane et al. ONCOLOGIST
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
- (2016) Camille Hua et al. JAMA Dermatology
- Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer
- (2016) Tanya J. Williams et al. JAMA Neurology
- Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer
- (2016) Mizuki Nishino et al. JAMA Oncology
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- (2016) Douglas B. Johnson et al. JAMA Oncology
- Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature
- (2016) Joshua E. Reuss et al. Journal for ImmunoTherapy of Cancer
- Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
- (2016) Lucie Heinzerling et al. Journal for ImmunoTherapy of Cancer
- Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
- (2016) Noha Abdel-Wahab et al. PLoS One
- Systematic review: colitis associated with anti-CTLA-4 therapy
- (2015) A. Gupta et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- C-Reactive Protein, Fecal Calprotectin and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis
- (2015) Mahmoud H Mosli et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Antiviral prophylaxis in patients with solid tumours and haematological malignancies—update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)
- (2015) Michael Sandherr et al. ANNALS OF HEMATOLOGY
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- How I treat refractory thrombotic thrombocytopenic purpura
- (2015) Farzana A. Sayani et al. BLOOD
- Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After Surgery
- (2015) Emily K. Wright et al. GASTROENTEROLOGY
- Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
- (2015) Omar Abdel-Rahman et al. Immunotherapy
- Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
- (2015) Hansje-Eva Teulings et al. JOURNAL OF CLINICAL ONCOLOGY
- Toxicities of Immunotherapy for the Practitioner
- (2015) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab-induced colitis in patients with metastatic melanoma
- (2015) Kara M. De Felice et al. MELANOMA RESEARCH
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab
- (2015) S. H. Tirumani et al. Cancer Immunology Research
- Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
- (2015) Ahmad A. Tarhini et al. Journal for ImmunoTherapy of Cancer
- Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
- (2015) Heinz Läubli et al. Journal for ImmunoTherapy of Cancer
- Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study
- (2014) L. Min et al. CLINICAL CANCER RESEARCH
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
- (2014) Alexander T. Faje et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer: An American Society of Clinical Oncology Clinical Practice Guideline Adaptation
- (2014) Julienne E. Bower et al. JOURNAL OF CLINICAL ONCOLOGY
- Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults With Cancer: An American Society of Clinical Oncology Guideline Adaptation
- (2014) Barbara L. Andersen et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement
- (2014) Jacqueline Jonklaas et al. THYROID
- Opportunistic infections in patients treated with immunotherapy for cancer
- (2014) Chrisann Kyi et al. Journal for ImmunoTherapy of Cancer
- Organizing Pneumonia as a Side Effect of Ipilimumab Treatment of Melanoma
- (2013) Igor Z. Barjaktarevic et al. CHEST
- Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial
- (2012) Chester V. Oddis et al. ARTHRITIS AND RHEUMATISM
- Anti–Cytotoxic T-Cell Lymphocyte Antigen-4–Induced Regression of Spinal Cord Metastases in Association With Renal Failure, Atypical Pneumonia, Vision Loss, and Hearing Loss
- (2012) Caroline Voskens et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- More on Hemophilia A Induced by Ipilimumab
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association
- (2012) Jeffrey R. Garber et al. THYROID
- Building better guidelines with BRIDGE-Wiz: development and evaluation of a software assistant to promote clarity, transparency, and implementability
- (2011) Richard N Shiffman et al. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
- Hemophilia A Induced by Ipilimumab
- (2011) Julie Delyon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe interstitial pneumonitis associated with the administration of taxanes
- (2010) Shigeyuki Nagata et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Advances in the understanding of acquired haemophilia A: implications for clinical practice
- (2009) Peter W. Collins et al. BRITISH JOURNAL OF HAEMATOLOGY
- Infliximab for the treatment of refractory scleritis
- (2009) P. Doctor et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Ipilimumab: controversies in its development, utility and autoimmune adverse events
- (2009) Jeffrey Weber CANCER IMMUNOLOGY IMMUNOTHERAPY
- CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
- (2009) Erika von Euw et al. Journal of Translational Medicine
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started